# Bioequivalence Study of Olaparib Tablets Under Fasting and Fed Conditions in Healthy Subjects

> **NCT06360445** · PHASE1 · COMPLETED · sponsor: **CSPC Ouyi Pharmaceutical Co., Ltd.** · enrollment: 102 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** Olaparib Tablet test formulation 100mg
- **DRUG:** Olaparib Tablet reference formulation 100mg
- **DRUG:** Olaparib Tablet test formulation 150mg
- **DRUG:** Olaparib Tablet reference formulation 150mg

## Key facts

- **NCT ID:** NCT06360445
- **Lead sponsor:** CSPC Ouyi Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-26
- **Primary completion:** 2022-08-21
- **Final completion:** 2022-08-21
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2024-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06360445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06360445, "Bioequivalence Study of Olaparib Tablets Under Fasting and Fed Conditions in Healthy Subjects". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT06360445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*